Last updated: January 21, 2021
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Overall Status: Completed
Phase
3
Condition
Atopic Dermatitis
Hives (Urticaria)
Scalp Disorders
Treatment
N/AClinical Study ID
NCT03908970
271-102-00007
Ages 15-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of AD based on the Japanese Dermatological Association's criteria
- History of AD for at least 3 years
- Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% ofbody surface area (BSA, excluding scalp) at the screening and baseline examinations
- IGA score of 2 or 3 at the screening and baseline examinations
Exclusion
Exclusion Criteria:
- Subjects who have an AD or contact dermatitis flare-up defined as a rapidintensification of AD, within 28 days prior to the baseline examination
Study Design
Total Participants: 364
Study Start date:
March 25, 2019
Estimated Completion Date:
December 28, 2019
Connect with a study center
Kitago Hifuka Clinic
Sapporo,
JapanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.